FDA Approves Mesenchymal Stromal Cell Therapy for Refractory Acute GVHD in Kids Medpage Today
FDA Approves Mesenchymal Stromal Cell Therapy for Refractory Acute GVHD in Kids Medpage Today
FDA Grants First-Ever Approval for MSC Therapy to Australian Company Mesoblast After Attempting for 4 Years geneonline
Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges Benzinga
Mesoblast finally pushes GvHD cell therapy over finish line pharmaphorum
Mesenchymal stem cells (MSCs) are a heterogeneous subset of stromal stem cells that can be isolated from many adult tissues. They can differentiate into cells of the mesodermal lineage, such as adipocytes, osteocytes and chondrocytes, as well as cells of other embryonic lineages. MSCs can interact with cells of both the innate and adaptive immune systems, leading to the modulation of several effector functions.
Mesoblast's RYONCIL is the First U.S.
FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease PR Newswire
RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead MarketWatch
An injury-induced mesenchymal-epithelial cell niche coordinates regenerative responses in the lung Science
New insights into survival of breast cancer cells in the bone marrow News-Medical.Net
Recent Comments